ASKG915

Phase 2Biologic

AAskGene Pharma, Inc.

ASKG915 is one of 11 biologic programs targeting Selected Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Selected Advanced Solid TumorsRecruiting

Selected Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Selected Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

6 2

Elunate

Takeda

Phase 2

1 3

Taxotere

AAvyxa

Phase 2

2 4

YL201

MMediLink Therapeutics (Suzhou) Co., Ltd.

Phase 2

1 5

Alimta

SShawn Eagle

Phase 1

2 6

Alimta

EEagle Pharmaceuticals, Inc.

Phase 1

1 7

Paraplatin

AAvyxa

Phase 1

1 8

MEDI5752

AstraZeneca

Phase 1

1 9

Q702

QQurient Co., Ltd.

Phase 2

1 10

ASKG915

AAskGene Pharma, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Selected Advanced Solid Tumors

NCT05867420

Clinical

Trials by Indication[1]

Selected Advanced Solid Tumors1 trial

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Recruiting·AAskGene Pharma, Inc.·Phase 1/2·NCT05867420·594 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ASKG915. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASKG915 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASKG915. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AskGene Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAskGene Pharma, Inc.

ASKG915

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Selected Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News